GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » 12-1 Month Momentum %

Hemogenyx Pharmaceuticals (LSE:HEMO) 12-1 Month Momentum % : -22.78% (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-21), Hemogenyx Pharmaceuticals's 12-1 Month Momentum % is -22.78%.

The industry rank for Hemogenyx Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

LSE:HEMO's 12-1 Month Momentum % is ranked better than
54.36% of 1481 companies
in the Biotechnology industry
Industry Median: -26.73 vs LSE:HEMO: -22.78

Competitive Comparison of Hemogenyx Pharmaceuticals's 12-1 Month Momentum %

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 12-1 Month Momentum % falls into.



Hemogenyx Pharmaceuticals  (LSE:HEMO) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemogenyx Pharmaceuticals  (LSE:HEMO) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Hemogenyx Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines